- Home
- PDCO vs NAMS Comparison
PDCO vs NAMS Comparison
Compare PDCO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCO
- NAMS
- Stock Information
- Founded
- PDCO 1877
- NAMS 2019
- Country
- PDCO United States
- NAMS Netherlands
- Employees
- PDCO N/A
- NAMS N/A
- Industry
- PDCO Medical Specialities
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- PDCO Health Care
- NAMS Health Care
- Exchange
- PDCO Nasdaq
- NAMS Nasdaq
- Market Cap
- PDCO 1.9B
- NAMS 1.7B
- IPO Year
- PDCO 1992
- NAMS N/A
- Fundamental
- Price
- PDCO $30.91
- NAMS $26.52
- Analyst Decision
- PDCO Hold
- NAMS Strong Buy
- Analyst Count
- PDCO 7
- NAMS 6
- Target Price
- PDCO $27.10
- NAMS $36.20
- AVG Volume (30 Days)
- PDCO 1.7M
- NAMS 1.4M
- Earning Date
- PDCO 12-05-2024
- NAMS 02-06-2025
- Dividend Yield
- PDCO 3.36%
- NAMS N/A
- EPS Growth
- PDCO N/A
- NAMS N/A
- EPS
- PDCO 1.72
- NAMS N/A
- Revenue
- PDCO $6,554,872,000.00
- NAMS $33,594,000.00
- Revenue This Year
- PDCO $2.74
- NAMS $129.49
- Revenue Next Year
- PDCO $3.25
- NAMS N/A
- P/E Ratio
- PDCO $17.96
- NAMS N/A
- Revenue Growth
- PDCO 0.05
- NAMS 78.77
- 52 Week Low
- PDCO $19.45
- NAMS $10.29
- 52 Week High
- PDCO $31.79
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- PDCO 84.41
- NAMS 68.38
- Support Level
- PDCO $30.85
- NAMS $24.40
- Resistance Level
- PDCO $31.79
- NAMS $27.29
- Average True Range (ATR)
- PDCO 0.51
- NAMS 1.57
- MACD
- PDCO 0.91
- NAMS 0.63
- Stochastic Oscillator
- PDCO 92.02
- NAMS 94.52
About PDCO Patterson Companies Inc.
Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.